WOCKPHARMANSEWockhardt Limited· PharmaceuticalsMediumPositive
Announced Fri, 12 Sept · 18:16 IST

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider, has voluntarily assigned an ESG rating of 68 (Strong) for the Financial Year 2024-25 as part of its annual ESG assessment process.

Business Updates View source PDF

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Wockhardt Limited has received an ESG rating of 68, which is classified as 'Strong', from ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider. This rating was assigned voluntarily as part of the provider's annual ESG assessment process for Financial Year 2024-25. The disclosure was made under SEBI's Listing Obligations and Disclosure Requirements Regulation 30. A 'Strong' ESG rating suggests the company performs well on environmental, social, and governance parameters compared to industry peers.

Likely market impact

A strong ESG rating can enhance Wockhardt's appeal to ESG-focused institutional investors and may support its sustainability credentials, but it is unlikely to have an immediate direct impact on stock price or financial performance.